ArticlePloS one2011
Reassessment of blood gene expression markers for the prognosis of relapsing-remitting multiple sclerosis.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Mice deficient of G-protein coupled receptor 3 (GPR3) developed severe experimental autoimmune uveitis (EAU) through increased effector T cell activities.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Genome-Wide Expression Profile in People with Optic Neuritis Associated with Multiple Sclerosis.Biomedicines · 2023Article
- An Enhanced Multiple Sclerosis Disease Diagnosis via an Ensemble Approach.Diagnostics (Basel, Switzerland) · 2022Article
- Elastic net-based prediction of IFN-β treatment response of patients with multiple sclerosis using time series microarray gene expression profiles.Scientific reports · 2019Article
- Pharmacogenomics of Multiple Sclerosis: A Systematic Review.Frontiers in neurology · 2019Review
- Towards a better understanding of the cannabinoid-related orphan receptors GPR3, GPR6, and GPR12.Drug metabolism reviews · 2018Review
- A Glycoengineered Interferon-β Mutein (R27T) Generates Prolonged Signaling by an Altered Receptor-Binding Kinetics.Frontiers in pharmacology · 2018Article
- Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?Frontiers in pharmacology · 2018Review
- No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.BMC neurology · 2015Article
- Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.Expert review of clinical immunology · 2015Review
- Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.Inflammopharmacology · 2014Article
- Article
- Article
- Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.Molecular neurobiology · 2013Article
- Role of toll-like receptors in multiple sclerosis.American journal of clinical and experimental immunology · 2013Article
- Microwave and magnetic (M(2) ) proteomics of the experimental autoimmune encephalomyelitis animal model of multiple sclerosis.Electrophoresis · 2012Article
- Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.Journal of neuroinflammation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite considerable advances in the treatment of multiple sclerosis, current drugs are only partially effective. Most patients show reduced disease activity with therapy, but still experience relapses, increasing disability, and new brain lesions. Since there are no reliable clinical or biological markers of disease progression, long-term prognosis is difficult to predict for individual patients. We identified 18 studies that suggested genes expressed in blood as predictive biomarkers. We validated the prognostic value of those genes with three different microarray data sets comprising 148 patients in total. Using these data, we tested whether the genes were significantly differentially expressed between patients with good and poor courses of the disease. Poor progression was defined by relapses and/or increase of disability during a two-year follow-up, independent of the administered therapy. Of 110 genes that have been proposed as predictive biomarkers, most could not be confirmed in our analysis. However, the G protein-coupled membrane receptor GPR3 was expressed at significantly lower levels in patients with poor disease progression in all data sets. GPR3 has therefore a high potential to be a biomarker for predicting future disease activity. In addition, we examined the IL17 cytokines and receptors in more detail and propose IL17RC as a new, promising, transcript-based biomarker candidate. Further studies are needed to better understand the roles of these receptors in multiple sclerosis and its treatment and to clarify the utility of GPR3 and IL17RC expression levels in the blood as markers of long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.